Home / Healthcare / Can-Fite BioPharma Ltd. - Product Pipeline Review - 2015

Can-Fite BioPharma Ltd. - Product Pipeline Review - 2015

Published: Apr 2015 | No Of Pages: 33 | Published By: Global Markets Direct

Can-Fite BioPharma Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Can-Fite BioPharma Ltd. - Product Pipeline Review - 2015', provides an overview of the Can-Fite BioPharma Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Can-Fite BioPharma Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Can-Fite BioPharma Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Can-Fite BioPharma Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Can-Fite BioPharma Ltd.'s pipeline products

Reasons to buy

- Evaluate Can-Fite BioPharma Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Can-Fite BioPharma Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Can-Fite BioPharma Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Can-Fite BioPharma Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Can-Fite BioPharma Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Can-Fite BioPharma Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Can-Fite BioPharma Ltd. Snapshot 4
Can-Fite BioPharma Ltd. Overview 4
Key Information 4
Key Facts 4
Can-Fite BioPharma Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
Can-Fite BioPharma Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Can-Fite BioPharma Ltd. - Pipeline Products Glance 9
Can-Fite BioPharma Ltd. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Can-Fite BioPharma Ltd. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Can-Fite BioPharma Ltd. - Drug Profiles 12
CF-101 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
CF-102 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CF-602 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Can-Fite BioPharma Ltd. - Pipeline Analysis 17
Can-Fite BioPharma Ltd. - Pipeline Products by Target 17
Can-Fite BioPharma Ltd. - Pipeline Products by Route of Administration 18
Can-Fite BioPharma Ltd. - Pipeline Products by Molecule Type 19
Can-Fite BioPharma Ltd. - Pipeline Products by Mechanism of Action 20
Can-Fite BioPharma Ltd. - Recent Pipeline Updates 21
Can-Fite BioPharma Ltd. - Dormant Projects 29
Can-Fite BioPharma Ltd. - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
CF-101 30
CF-502 30
Can-Fite BioPharma Ltd. - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

Can-Fite BioPharma Ltd., Key Information 4
Can-Fite BioPharma Ltd., Key Facts 4
Can-Fite BioPharma Ltd. - Pipeline by Indication, 2015 6
Can-Fite BioPharma Ltd. - Pipeline by Stage of Development, 2015 7
Can-Fite BioPharma Ltd. - Monotherapy Products in Pipeline, 2015 8
Can-Fite BioPharma Ltd. - Phase II, 2015 9
Can-Fite BioPharma Ltd. - Phase I, 2015 10
Can-Fite BioPharma Ltd. - Preclinical, 2015 11
Can-Fite BioPharma Ltd. - Pipeline by Target, 2015 17
Can-Fite BioPharma Ltd. - Pipeline by Route of Administration, 2015 18
Can-Fite BioPharma Ltd. - Pipeline by Molecule Type, 2015 19
Can-Fite BioPharma Ltd. - Pipeline Products by Mechanism of Action, 2015 20
Can-Fite BioPharma Ltd. - Recent Pipeline Updates, 2015 21
Can-Fite BioPharma Ltd. - Dormant Developmental Projects,2015 29
Can-Fite BioPharma Ltd. - Discontinued Pipeline Products, 2015 30
Can-Fite BioPharma Ltd., Other Locations 31
Can-Fite BioPharma Ltd., Subsidiaries 31

Can-Fite BioPharma Ltd. - Pipeline by Top 10 Indication, 2015 6
Can-Fite BioPharma Ltd. - Pipeline by Stage of Development, 2015 7
Can-Fite BioPharma Ltd. - Monotherapy Products in Pipeline, 2015 8
Can-Fite BioPharma Ltd. - Pipeline by Top 10 Target, 2015 17
Can-Fite BioPharma Ltd. - Pipeline by Top 10 Route of Administration, 2015 18
Can-Fite BioPharma Ltd. - Pipeline by Top 10 Molecule Type, 2015 19
Can-Fite BioPharma Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 20

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +